EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Monday, May 26, 2025, 10:00 Hrs [IST] GSK ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company announced that the ...

The two active substances are antivirals that inhibit HIV reverse transcriptase through incorporation into the viral DNA, ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...

LUND, SE / ACCESS Newswire / May 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical stage biotechnology ...

GSK said the European Medicines Agency's committee responsible for human medicines has recommended the approval for its Blenrep drug. The U.K. pharma company on Friday said an approval decision by ...

Autolus Therapeutics (NASDAQ:AUTL) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed obecabtagene autoleucel for leukemia treatment. Issuing ...